160 related articles for article (PubMed ID: 28327903)
1. Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation.
Schrader J; Henes FO; Perez D; Burdak-Rothkamm S; Stein A; Izbicki JR; Lohse AW
Ann Oncol; 2017 Apr; 28(4):904-905. PubMed ID: 28327903
[No Abstract] [Full Text] [Related]
2. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
[TBL] [Abstract][Full Text] [Related]
4. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
5. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
[TBL] [Abstract][Full Text] [Related]
6. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
Huynh H; Hao HX; Chan SL; Chen D; Ong R; Soo KC; Pochanard P; Yang D; Ruddy D; Liu M; Derti A; Balak MN; Palmer MR; Wang Y; Lee BH; Sellami D; Zhu AX; Schlegel R; Huang A
Mol Cancer Ther; 2015 May; 14(5):1224-35. PubMed ID: 25724664
[TBL] [Abstract][Full Text] [Related]
7. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
9. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Maxwell JE; Sherman SK; Howe JR
Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
[TBL] [Abstract][Full Text] [Related]
10.
Asprino PF; Linck RDM; Cesar J; Freitas FP; Koyama FC; Riechelmann RSP; Costa FP; Hoff PMG; Galante PAF; Meyer D; Camargo AA; Sabbaga J
Endocr Relat Cancer; 2018 Feb; 25(2):L1-L5. PubMed ID: 29167182
[No Abstract] [Full Text] [Related]
11. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
12. mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Orr-Asman MA; Chu Z; Jiang M; Worley M; LaSance K; Koch SE; Carreira VS; Dahche HM; Plas DR; Komurov K; Qi X; Mercer CA; Anthony LB; Rubinstein J; Thomas HE
Mol Cancer Ther; 2017 Nov; 16(11):2432-2441. PubMed ID: 28864682
[TBL] [Abstract][Full Text] [Related]
13. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.
Papaxoinis G; Syrigos K; Saif MW
Discov Med; 2016 May; 21(117):391-402. PubMed ID: 27355335
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia.
Potter SL; Venkatramani R; Wenderfer S; Graham BH; Vasudevan SA; Sher A; Wu H; Wheeler DA; Yang Y; Eng CM; Gibbs RA; Roy A; Plon SE; Parsons DW
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27748010
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
17. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
18. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of high-grade pancreatic neuroendocrine neoplasms with everolimus.
Genç CG; Klümpen HJ; Denecke T; Wiedenmann B; Pavel M
Acta Oncol; 2018 May; 57(5):686-688. PubMed ID: 29126357
[No Abstract] [Full Text] [Related]
20. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
